If HCPs Do Not Understand It, Does Performance Even Matter?

By Javier M. Floren, CEO of 3DforScience - Global Scientific Communications.

We need to have an honest conversation about what we really mean when we say we are data-driven in pharma marketing.

We are performance-driven. And that is not the same thing.

Performance-driven means we optimize for numbers that are easy to report. Views. Clicks. Dwell time. Completion rate. Clean dashboards. Nice charts for the next internal meeting.

But let me ask you something:

When was the last time a completion rate helped an HCP truly understand a complex mechanism of action?
When did a click through rate build real trust in a new therapy?

It did not.

We measure everything except understanding.

And in our world, understanding is the only metric that really matters.

We are communicating science that will influence clinical decisions and patient outcomes. If the mechanism feels dense, if the data feels overwhelming, if the narrative forces the audience to decode instead of understand, no optimization will fix that later.

This is where I believe we are underestimating data.

Data is not the enemy of creativity. It is not here to make our work mechanical. Data is a mirror. It shows us where friction appears. Where confusion starts. Where curiosity spikes. Where attention fades.

If viewers consistently drop at a specific moment, what is happening there?

• Are we losing clarity?
• Are we overloading them?
• Are we protecting ourselves with complexity instead of serving them with simplicity?

Those signals are not threats. They are invitations to improve.

I have always believed that science should be understood, not decoded. When someone has to work too hard to follow the story, we have made it about us, not about them. Data can reveal when decoding is happening. When the audience is working harder than they should.

And this connects directly to personalization.

Not personalization in a superficial way. Not just swapping a name or a banner. I mean meaningful personalization.

Different specialties care about different aspects of the same molecule. A hospital specialist and a community physician do not look at the same endpoints with the same intensity. So, why are we still telling exactly the same story to everyone?

We already have the tools to adapt narratives based on interest and behavior. This is not futuristic. It is possible now. But the intention has to be right. It should serve clarity and relevance, not just better numbers.

The future of pharma communication is not more content.

It is smarter content. More intentional content. Content that respects time, context, and cognitive load.

To get there, we need a cultural shift.

We need to stop asking only “how did it perform?”
And start asking, “what did we learn about our audience?”

What confused them.
What resonated.
What created doubt.
What built confidence.

Are we brave enough to redesign a beautiful asset because the data shows it was misunderstood?

When data becomes a conversation instead of a report, everything changes. We stop defending our materials. We start refining them. We stop celebrating impressions. We start designing for comprehension.

And when we design for understanding, our videos are not just watched.

They are felt.

In pharma, where trust and clarity shape real decisions, that difference is not small.

It is everything.